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ABSTRACT  9 
Purpose: The most effective intravesical treatment of non-muscle-invasive bladder cancer is 10 
instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). BCG stimulates the release 11 
of cytokines, contributing directly or indirectly to its effectiveness. However, the function of specific 12 
cytokines is not well understood.  13 
Methods: We have undertaken a non-systematic review of primary evidence regarding cytokine 14 
detection, activation and response in BCG patients.  15 
Results: Cytokines IL-2, IL-8 and TNFα appear to be essential for effective BCG therapy and non-16 
recurrence, whilst IL-10 may have an inhibitory effect on BCG responses. IL-2, IL-8, TRAIL and TNFα 17 
are potentially predictive of response to BCG. Alterations in genes encoding cytokines may also 18 
affect responses. 19 
Conclusions: There are significant data showing the association of certain cytokines with successful 20 
BCG treatment, and which may be useful predictive markers. Isolating those cytokines mediating 21 
efficacy may hold the key to ameliorating BCG’s side effects and improving efficacy and patient 22 
compliance. 23 
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INTRODUCTION  24 
In the past few decades BCG intravesical immunotherapy following transurethral resection (TURBT) 25 
of non-muscle-invasive bladder cancer (NMIBC) has been established as the most effective adjuvant 26 
therapy, significantly reducing tumour progression and local recurrence (1). Intravesical BCG 27 
immunotherapy is arguably the most successful immunotherapy modality employed clinically to 28 
date. However, since the discovery of its benefits in bladder cancer therapy in the 1970s (2), the 29 
mechanisms of its actions have remained unclear.  30 
As the bladder is an enclosed and confined compartment, BCG can be stored at high concentrations, 31 
theoretically resulting in a durable and continuous exposure (although the vast majority of BCG is 32 
cleared within several hours after instillation (3), some bacteria may persist in the bladder for many 33 
weeks or months (4, 5)). Ideally, an intact immune system is also required for successful BCG 34 
treatment; however, efficacy and safety have also been demonstrated in some groups of 35 
immunologically compromised patients with bladder cancer (6). BCG induces a mass release of 36 
cytokines and inflammatory cells into the bladder, and these cytokines have different roles, being 37 
anti-neoplastic, inflammatory, or inhibitory.  38 
Despite high clinical efficacy, BCG immunotherapy is associated with significant side effects from 39 
local haematuria and dysuria, to life threatening sepsis (7). Such side effects often mean that 40 
patients do not complete the full course of induction or maintenance, potentially leading to worse 41 
outcomes: although generally considered safe, BCG has local and systemic side effects that lead to 42 
treatment cessation in up to 30% of patients, or to a delay or reduction in the number of instillations 43 
in 55-83% of patients (8). Therefore, although BCG is effective, it is only suitable for intermediate 44 
and high risk NMIBC patients in which current guidelines recommend one immediate instillation of 45 
chemotherapy post-TURBT, followed by a minimum of one year of BCG intravesical immunotherapy 46 
or further instillations of chemotherapy (7). A better understanding of BCG’s mechanism of action 47 
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may allow its anti-neoplastic actions to be isolated, potentially improving efficacy and ameliorating 48 
side effects. Furthermore, some patients fail to respond to BCG treatment, and identifying these 49 
patients at an early stage (when other treatments may be curative) remains difficult. There is 50 
evidence to suggest that certain cytokines may be predictive of BCG efficacy, although such cytokine 51 
profiles are not yet being used clinically. 52 
For immunotherapy to be effective, three basic steps need to be fulfilled. Firstly, there must be 53 
uptake of the therapeutic agent into the tumour cells. In the bladder, fibronectin is responsible for 54 
the uptake of BCG (9, 10). Then, an immune response must be induced, either by direct activation in 55 
response to microbial products, or by the presentation of antigen by antigen presenting cells (APCs) 56 
to effector cells. Finally, effector cells must migrate to the tumour and induce tumour cell killing. 57 
This review focuses on the role of individual cytokines as effectors, and their anti-neoplastic actions 58 
and prognostic utility in BCG therapy. 59 
 60 
METHODS 61 
A non-systematic search was undertaken using the NCBI/NIH library (PubMed) for articles published 62 
up to 2013 concerning the involvement of cytokines in BCG treatment for bladder cancer. Keywords 63 
used to conduct the search included ‘BCG,’ ‘cytokine,’ and ‘mechanisms.’ As the work progressed, 64 
individual cytokines were researched in greater depth (ie. ‘BCG and IL-8 mechanism’), as well as 65 
‘macrophage response’, ‘gene variants’ and ‘cytokine predictor,’ all reviewed in conjunction with 66 
‘BCG’ and ‘bladder cancer.’  67 
68 
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RESULTS 69 
The Immune Response 70 
To understand the cytokine response, it is important to clarify the normal T cell lymphocytic 71 
response. Cytokines are central to cell-mediated immunity and antibody responses. T lymphocytes 72 
have antigen recognition receptors that can bind to antigen and induce immune responses, 73 
eventually leading to the destruction of the target cell. The two main subsets of T cells are CD4 74 
helper T cells and CD8 cytotoxic T cells. The identification of such distinct subsets of T helper cells 75 
capable of producing different cytokine profiles (differentially polarised from a non-polarised naïve 76 
(Th0) precursor cell) led to the conceptualisation of Th1 and Th2 subsets. While the majority of 77 
interest has involved CD4+ T helper cells, CD8+ T cells are also polarised to form Tc1 and Tc2 subsets 78 
(11, 12). The polarisation of CD8+ T cells to Tc1/Tc2 has similar stimulating factors to the polarisation 79 
of CD4+ T cells (13). Subsequently, there have been numerous Th subsets identified, although the 80 
two main categories remain Th1 and Th2. Th1 cytokines produce pro-inflammatory responses and 81 
the main cytokine secreted is IFNγ, in addition to IL-2, IL-12, TNFα, etc. It is this element of the 82 
immune response which is believed to be key to anti-tumour responses (14). In order to protect the 83 
body from inflammatory cellular damage, Th2 cytokines counteract the inflammatory response with 84 
IL-4, 5, 6, 10, and 13; Th2 cytokines are also involved in antibody reactions (11). IL-17 producing T 85 
cells are also noteworthy (e.g. Th17 cells): similarly to Th1 cells, Th17 are pro-inflammatory but are 86 
induced under very different conditions to Th1 cells (reviewed extensively elsewhere (15, 16)).  87 
There is a wealth of data regarding response to BCG as an anti-tuberculosis (TB) vaccine, and it is 88 
increasingly recognised that IL-17 and the archetypal Th1 cytokine, IFNγ, are closely linked in the 89 
response to BCG vaccine. Indeed, protective immunity is at least partially dependant on an effective 90 
Th1 response (17), for which it is proposed that IL-17 is also required (18). IL-17 additionally has roles 91 
in recruiting neutrophils through the induction of IL-8 (discussed later). IL-8 mediated neutrophil 92 
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recruitment has been proposed to be at the heart of the anti-tumour activity of BCG (19, 20), and in 93 
murine models IL-17 is required for BCG immunotherapy efficacy (21). Data from BCG vaccine 94 
studies have shown that neutrophils are efficacious, but a strong prolonged recruitment is 95 
associated with pathology (22); how this relates to the deleterious side effects of BCG 96 
immunotherapy is yet to be determined.  97 
It would seem unlikely that anti-tumour T cells are directly activated by BCG; rather, an indirect 98 
activation by presentation of tumour antigens in an inflammatory setting (i.e. alongside the response 99 
to BCG) could be possible, in which cytokines are essential. Likewise, the killing of tumour cells may 100 
be incidental, i.e. they are killed by BCG-specific T cells if infected by BCG. Notwithstanding, the 101 
ability of tumour cells to present antigen is associated with response to BCG immunotherapy (23, 102 
24).  103 
 104 
Cytokines in BCG 105 
The large number of publications investigating cytokine involvement in BCG immunotherapy is 106 
derived from the discovery of elevated urinary levels of macrophages, T cells, NK cells and dendritic 107 
cells post BCG instillation (25, 26), which suggest infiltration of lymphocytes into the bladder wall. 108 
The internalisation of BCG by tumour cells or normal urothelial cells is likely an early step in this 109 
cascade (3), with the tumour/urothelial cells thereafter seemingly functioning like antigen-110 
presenting cells (APCs) to induce cytokine production (27, 28). The rationale for investigating 111 
cytokine therapy alone or the administration of cytokines alongside BCG stems from the observation 112 
that live BCG creates the side effects, whilst cytokines alone are much better tolerated. 113 
Furthermore, it is thought that live BCG is not required to induce the bladder inflammatory cascade 114 
(29) (although live BCG is required to induce the APC-like characteristics described above). For 115 
example, gamma-irradiated but metabolically active BCG has demonstrated activity in vitro similar 116 
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to that of live BCG with respect to tumour growth inhibition and cytokine production (30). 117 
Furthermore, therapies utilising cell wall components derived from heat-killed BCG or other 118 
mycobacteria have also shown efficacy in vitro and in vivo, with an improved toxicity profile (31, 32). 119 
Such studies also suggest potential for using cell wall extracts in patients where BCG has failed (31, 120 
32). Killed BCG and mycobacterial subcomponents can also stimulate the release of TNF-related 121 
apoptosis-inducing ligand (TRAIL) from neutrophils (20, 33) (TRAIL is a member of the TNF family 122 
that induces apoptosis in cancerous cells (29)). It is feasible that live BCG may only be required for 123 
initial BCG priming, and may not be necessary throughout all phases of BCG therapy, potentially 124 
improving safety and tolerability (10). In addition, although single cytokine therapy has not yielded 125 
promising results (34, 35), combinations of BCG with cytokines have been more successful (29), 126 
demonstrating that the cytokine mechanisms are complex and require more investigation. 127 
Many studies have found the presence of a variety of cytokines in urine and serum post BCG 128 
instillation (see Supplementary Table 1), including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, TNFα, and IFNγ 129 
(25, 26). These and other cytokines are discussed in more detail below. 130 
Jackson et al. treated 25 patients with carcinoma in situ with six weekly instillations of BCG; they 131 
then used immunoenzymatic assays on urine samples for the detection of cytokines (25). They 132 
demostrated that, with the exception of IL-6, the cytokines listed above are not detectable in the 133 
urine of untreated patients, and that their appearance in urine after treatment was distributed over 134 
the treatment period. Table 1 summarises their findings. The recognition that most cytokines are 135 
only present after several instillations was also noted by Kresowik et al. where leukocyte levels 136 
peaked after the 6th instillation of BCG (29). This suggests that the immune response in the bladder is 137 
a delayed-type hypersensitivity response. Jackson’s research found IL-1β, IL-6, IL-8, IL-10 and sICAM1 138 
after the first instillation, but IL-2, TNFα and IFNγ were only found later. This may reflect the source 139 
of these cytokines, given that resident macrophages secrete IL-1 and IL-6, but cytokines such as IL-2 140 
and IFNγ are only produced after T cell activation following repeated BCG instillations (25). 141 
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Another more recent study by Shintani et al. demonstrated that urinary GCSF, IL-1β, and IL-8 levels 142 
were significantly higher after the sixth instillation than pre-instillation. However, they did not 143 
record significant increases in urinary IFNγ or IL-12, despite being key cytokines in CD4 Th1 144 
responses (26). Böhle et al. showed that IFNγ and IL-12 might be secreted in topical CD4 cells in the 145 
bladder wall (36), but this was not reflected in Shintani’s results. It may be that IL-12 induced by BCG 146 
is produced earlier than other Th1 cytokines; Shintani’s monitoring period between 4 and 24 hours 147 
may have missed the maximum secretions of IL-12, although the stability of IL-12 (and all cytokines) 148 
in the urine may also be problematic. It is also feasible that the levels needed to induce responses in 149 
the tumour microenvironment may be undetectable in the urine. 150 
 151 
Functions of individual cytokines and their actions stimulated by BCG 152 
IL-1α and IL-1β (IL-1) are pro-inflammatory cytokines, whilst IL-1Ra is anti-inflammatory. These IL-1 153 
derivatives compete for IL-1 receptor binding to regulate immune and inflammatory responses. 154 
Higher expression of IL-1 has been associated with tissue damage and aggressive tumours and there 155 
is a strong association of IL-1Ra with bladder cancer, but data specific to IL-1Ra and its relationship 156 
with BCG is not widely available (37). Böhle et al. proposed that IL-1 may function by inducing IL-2, 157 
macrophages and cytotoxic T lymphocytes (36); IL-1 may also interact with IL-2 and INFγ to induce 158 
the NK cell killing of cancer cells (38) . 159 
IL-2 is involved in T cell proliferation and differentiation. IL-2 was consistently elevated in urine 160 
samples of all patients within 24 hours post-BCG instillation in the study by Böhle et al., with 161 
maximum levels after 4 hours (36). Haaff et al. confirmed these findings, demonstrating maximal IL-2 162 
secretion after 4 hours (39). IL-2 is produced by Th1 cells, and it thus appears that BCG effectiveness 163 
correlates with preferential induction of Th1 cytokines (38) .  164 
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 IL-4 is an important cytokine in the activation of B cells, as well as Th2 lymphocyte development, 165 
along with IL-6 and IL-10. Sander et al. found a temporary increase in IL-4 levels in the urine within 166 
24 hours post BCG instillation (40), although Agarwal et al. showed reduced IL-4 levels in patients 167 
receiving combined immunotherapy (41). Table 1 also shows that Jackson et al. did not detect IL-4 in 168 
the urine of BCG patients, and confirmed that this was not due to insensitivity since IL-4 was 169 
detected in both lymphocyte tissue culture supernatants and ‘spiked’ urine (25). The relatively low 170 
amount of IL-4 compared to other cytokines suggests that Th2 responses are less dominant in BCG 171 
responses, consistent with the evidence above regarding the apparent importance of Th1 responses 172 
for BCG efficacy. Jackson et al. found an increase in IL-10 alongside the absence of IL-4, which is 173 
somewhat contradictory since they are both Th2 cytokines. However, IL-10 is now recognised not be 174 
exclusively produced by Th2 cells, having both regulatory roles and being produced by other cells, 175 
including Th1, Tr1 regulatory CD8+ T cells and Treg (15). In addition, IL-10 did not show a negative 176 
correlation with IL-2 and IFNγ, even though it acts to inhibit them(25). IL-10 is discussed in more 177 
detail later. 178 
IL-6 is one of the key cytokines in the acute phase response, and promotes neutrophil synthesis. It 179 
supports B cell growth and antagonises Treg cells. Following binding of BCG fibronectin attachment 180 
protein (FAP) to cellular fibronectin, IL-6 and other cytokines are produced by tumour cells, a 181 
process requiring BCG to be internalised by α5β1 integrin (10, 42-44) and leading to the necessary 182 
subsequent activation of NFkB and AP1 (42). Interestingly, the malignant transformation of 183 
urothelial cells may render them more susceptible to uptake of BCG (10, 45). Other mechanisms, 184 
such as the production of IL-17 by immune cells, may also contribute to the production of IL-6 (46). 185 
Furthermore, macrophages are well known to produce IL-6 in response to BCG (46, 47); as 186 
macrophages are present within the tumour stroma (48), these cells may also represent a notable 187 
source of IL-6 following intravesical BCG application.  188 
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IL-6 is able to influence a number of immune cell types, directly and indirectly through aiding 189 
recruitment by inducing expression of a variety of chemokines (49). Activation of signal transducers 190 
and activators of transcription (STAT)-3 by IL-6 promotes survival of T cells through up-regulation of 191 
Bcl-2 (50); likewise, IL-6 has also been shown to affect NK cell cytotoxicity (51). Conversely IL-6 also 192 
promotes tumour cell survival (52). IL-6 is also able to suppress IFNγ production through the 193 
induction of the transcription factor suppressor of cytokine signaling-1 (SOCS), while promoting IL-4 194 
(Th2) responses through nuclear factor of activated T cells (NFAT) activation (53). Autocrine signaling 195 
by IL-4 subsequently reinforces Th2 differentiation. However, as discussed, current studies do not 196 
consistently detect IL-4 following BCG therapy. Similarly, in studies of BCG as a vaccine, IL-10 rather 197 
than IL-4 dominates in response to BCG (54). These data suggest BCG produces IL-10+ non-Th2 198 
polarised cells, also consistent with the presence of IL-10 in urine following BCG therapy.  199 
Using immunohistochemistry, Cardillo et al demonstrated significantly higher levels of IL-6 in bladder 200 
tumours (55). Additionally, Zhang et al. investigated the relationship between cAMP production and 201 
IL-6 production, and found decreased cAMP and IL-6 production simultaneously in the presence of a 202 
specific adenylate cyclase inhibitor (44). This led to the hypothesis that IL-6 may be upregulated by 203 
BCG using a cAMP-dependent pathway. However, as illustrated above, this is unlikely to be the only 204 
pathway (44). 205 
IL-8 is an early cytokine in the inflammatory response, produced by a variety of immune and 206 
epithelial cells in response to bacterial products or other inflammatory cytokines, e.g. IL-17 (as 207 
mentioned above). IL-8 has significant chemokine functions, recruiting mainly neutrophils to the site 208 
of inflammation, thus driving the early stages of the innate immune response. As such, IL-8 has been 209 
shown to be elevated to high levels in the urine within hours of BCG instillation (56) which, as 210 
discussed later, may have prognostic value. 211 
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IL-10 decreases cytokine production by Th1 cells, cytotoxic T cell generation and antigen 212 
presentation (57). It achieves this by blocking MHC-II and the expression of co-stimulatory molecules 213 
on APCs, as well as by induction of co-inhibitory molecules (58). It has also been proposed that IL-10 214 
diminishes macrophage activity by reversing the effects of TNFα and IFNγ. Murine studies by Luo et 215 
al. using two bladder cancer cell lineages (MBT-2 and MB49, shown to have similar responses to 216 
BCG), demonstrated correlations between high IL-10 levels and decreased cytotoxic effector 217 
molecules (59). These studies lead to the conclusion that IL-10 could decrease macrophage toxicity 218 
against bladder cancer cells. Interestingly, data from BCG vaccine studies also indicate that BCG is 219 
capable of inducing IL-10 following chronic exposure (60, 61). It may therefore be possible to 220 
promote Th1 responses by IL-10 inhibition, and such approaches have been validated in preclinical 221 
animal models (62, 63) as discussed later.  222 
IL-12 immunomodulation has been met with tumour response in many malignancies, including 223 
bladder cancer models. It is thought that the anti-tumour effect is driven primarily by CD8+ T cells, 224 
and involves an increase of IFN-γ (64). In a study by Riemensberger et al. BCG therapy was 225 
ineffective in mice with IL-12 knockout (57). However, despite promising results in mice, trials on 226 
humans have been less successful (35). Weiss et al. administered recombinant human IL-12 in 227 
patients with recurrent NMIBCs, and this was associated with minimal toxicity, but also poor efficacy 228 
(35). 229 
IL-18 is secreted by BCG-activated macrophages, and activates NK cells and cytotoxic T lymphocytes 230 
(65, 66). Elevated urinary IL-18 levels are observed after BCG instillation (66, 67), and are associated 231 
with significantly longer disease-free survival (66). 232 
TNFα has been linked to many processes in cancer, such as cell transformation, proliferation, 233 
survival, invasion, angiogenesis and metastasis (37). Böhle et al. found a large increase in urinary 234 
TNFα following BCG instillation when compared to the control group (36), and Jackson et al.’s 235 
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studies found that TNFα levels were detected in later instillations (Table 1) (25). TNF-related 236 
apoptosis-inducing ligand (TRAIL) is a member of the TNF family that induces apoptosis in cancerous 237 
cells (29). In a study by Ludwig et al., BCG responders had significantly higher urinary TRAIL levels 238 
than non-responders (68); with subsequent BCG instillations, TRAIL was further increased. TRAIL 239 
secretion following BCG is neutrophil-dependent, and this same study showed that neutrophils 240 
stimulated by BCG were able to kill bladder cancer cells in a TRAIL-dependent manner. TRAIL seems 241 
to be unique to the BCG immune response (urine samples from urinary tract infections found lower 242 
levels of TRAIL (68)), although the stimulation of TRAIL does not appear to be completely dependent 243 
on live BCG: Kemp et al. found that TRAIL can be produced following stimulation with killed BCG and 244 
Toll-like receptor 2 and 4 agonists (20). In addition, murine studies have shown that instillations of 245 
dead BCG following previous live BCG treatment produce similar cytokine responses to live BCG 246 
alone (29). As the side effects of BCG are largely attributed to live BCG, this may be a useful strategy 247 
to diminish BCG’s adverse effects, although caution would be needed to ensure that full clinical 248 
efficacy is maintained; however, clinical trials may be warranted 249 
IFNγ is a pro-inflammatory cytokine. It enhances lymphocyte function, stimulates cell adhesion 250 
molecule expression, upregulates MHC expression (37), and has been shown to inhibit the growth of 251 
RT4, RT112 and MGH-U1 cell lines in vitro (69). Carriers of the IFNγ +874 A polymorphism are 252 
associated with a higher risk of recurrence after BCG immunotherapy (37), possibly as a result of 253 
decreased IFNγ production as observed in tuberculosis (70). However, Shintani et al found no 254 
significant urinary IFNγ increases between 4 hours and 24 hours even after the 6th instillation of BCG 255 
when compared with pre-instillation values (26). According to Böhle et al.’s investigations, IFNγ is a 256 
key cytokine in the CD4 response, in conjunction with IL-12 (36), but Shintani’s results do not reflect 257 
this (26). 258 
Intercellular adhesion molecules (ICAMs) are expressed at a higher level, along with MHC-II, 259 
following BCG instillation. They are detected immediately, and levels increase with repeated doses 260 
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of BCG, although they are not normally expressed by untreated bladder carcinoma cells (25). In vitro, 261 
cytokines such as TNFα, IFNγ and IL-1 can up-regulate the expression of MHC-II and ICAM-1. It is 262 
thought that ICAM-1 expression can enhance ligand binding of cytotoxic cells, whilst MHC-II can 263 
present antigen to CD4 T cells. This had led to the belief that ICAM-1 expression may predispose 264 
tumour cells to cell-mediated cytotoxicity (25). 265 
 266 
Predictive Cytokines 267 
The study of cytokines as predictors of response to BCG immunotherapy is also highly relevant. The 268 
cytokines observed to have the most promising predictive utility for BCG efficacy are IL-2, IL-8, TNFα, 269 
TRAIL, and possibly IL-18 (65, 71). Urinary levels of these cytokines may be essential for the success 270 
of BCG, or may be indicative of the magnitude or quality of the immune response. Such cytokines 271 
are not currently used as predictors of response in clinical practice, nor do we precisely understand 272 
the factors which determine their elevation.  273 
In particular, IL-2 and IL-8 are the most widely studied (see Table 2). Numerous studies have 274 
identified a significant association between higher IL-8 secretion and BCG responses (66, 72-74). For 275 
example, De Boer et al. suggest that IL-8 can be used as an indicator of efficacy 6 hours after 276 
instillation (56), and Shintani et al. found higher levels of IL-8 in the non-recurrence group within 4 277 
hours after the 6th instillation of BCG (26). However, there are a number of other studies which have 278 
failed to demonstrate this relationship (26, 75), including Sagnak et al. who, in contrast to the other 279 
studies, demonstrated that patients with lower IL-8 showed improved outcomes (76). Additional 280 
studies have shown IL-2 to also be predictive of response. For example, Watanabe et al. found 281 
higher levels of IL-2 in later instillations to be a strong predictive factor for a positive response to 282 
BCG therapy (72). However, they also found that IL-2 concentrations are variable depending upon 283 
the storage method of the urine samples: cytokine concentrations in urine samples before and after 284 
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freezing were different, and storage temperature caused variability. Indeed, the small sample size 285 
and differences in sampling make interpretation of these data difficult. Despite this, the suggestion 286 
that IL-2 is a predictive factor for BCG is supported by other studies (72, 75, 77, 78). Interestingly, 287 
Kaempfer et al. showed IL-2 gene expression in peripheral blood to be predictive of response (79); it 288 
would be of great interest to assess whether this relationship exists in a larger cohort of patients and 289 
using current methodologies. 290 
Urinary TRAIL appears in increased levels in BCG-responsive patients compared non-responders (20, 291 
68). As mentioned above, heat-killed BCG is also able to elicit comparable TRAIL/Apo-2L release from 292 
neutrophils as viable BCG (20). The potential of altering TRAIL expression to enhance BCG effect has 293 
also been proposed, for example by using a combination therapy of BCG and IFN-α, or even by direct 294 
intravesical recombinant TRAIL instillation (68). As well as increasing efficacy, it may permit a 295 
reduced BCG dose to achieve the same effects, thereby decreasing the potential for adverse effects. 296 
 297 
FUTURE PERSPECTIVE 298 
A full understanding of BCG’s mechanism of action in the treatment of bladder cancer remains 299 
elusive (10): IL-2, TNFα and INFγ levels appear to be much higher in urine post BCG, which suggests 300 
that the BCG reaction is predominantly Th1 mediated, yet the cellular origins of the cytokines do not 301 
appear to be divided into classical Th1 and Th2 sources, as demonstrated by contradicting levels of 302 
IL-10 and IL-4. In addition, the time lag between the appearance of different cytokines in different 303 
studies suggests variability in both individual cytokines and patients. See Figure 1.  304 
The future development of BCG immunotherapy for bladder cancer should therefore be directed 305 
towards three objectives:  306 
• Identifying patients most likely to benefit from treatment; 307 
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• Increasing efficacy using promotion and blockade of specific cytokines; 308 
• Reducing side effects and improving tolerability. 309 
Cytokines with possible predictive value have the potential to act as a screening method for patients 310 
who may or may not succeed with BCG treatment: IL-2, IL-8, TRAIL and TNFα appear to have a 311 
predictive relationship with BCG efficacy, with significantly higher IL-2 and IL-8 levels in responders 312 
compared to non-responders (Table 2). These cytokines appear within 6 hours post-instillation, and 313 
have strong positive correlations to successful BCG treatment and non-recurrence. However, these 314 
data are not consistent and so have not yet reached clinical practice. More recently, the IL-6:IL-10 315 
ratio has also demonstrated predictive utility (80). This area of research would benefit from further 316 
clarification and confirmatory studies since it could lead to efficient tests to identify the subgroup of 317 
patients who reap no benefit from BCG but whom suffer from side effects, in addition to reducing 318 
the delay to efficacious treatment (and reducing cost).  319 
The physiochemistry of the molecules being studied also needs to be considered and results 320 
interpreted carefully - cytokines can be unstable in biological fluids (78) (although IL-8 appears to be 321 
stable in urine for over 48 hours (73)), and the immunoassays performed may be affected by ionic 322 
strength, pH(25), protease activity, and soluble binding proteins. Uniform or standard units of 323 
measurement would also aid the interpretation and comparison of studies. Assessing the profiles of 324 
multiple cytokines is also costly, which is why the studies reviewed above rarely surpass 30 325 
individuals, or only a few cytokines are assessed in each study. Moreover, study patients are usually 326 
heterogeneous with regard to gender and ethnicity. Recent evidence demonstrates that existing 327 
BCG-specific responses (from vaccination, for example) may improve the BCG immunotherapy 328 
response in bladder cancer (81); since BCG vaccine efficacy has a significant ethnic bias (82, 83), it 329 
should be considered whether this may occur in the setting of BCG immunotherapy for bladder 330 
cancer. Additional complexity is provided by the seemingly differential induction of immune 331 
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responses and efficacy of the commonly-used BCG strains in both immunisation and NMIBC 332 
treatment (84, 85). For example, in vitro, Russian and Connaught strains induce significantly higher 333 
cytokine production (IL-6 and IL-8) and inhibition of tumour cell proliferation than Glaxo strain (85), 334 
and in a randomised controlled trial treatment with BCG Connaught conferred significantly greater 335 
5-yr recurrence-free survival compared with treatment with BCG Tice (86). In mice, BCG Connaught 336 
induces stronger Th1-biased responses, greater priming of BCG-specific CD8+ T cells, and more 337 
robust T-cell recruitment to the bladder than BCG Tice (86). Furthermore, different BCG vaccine 338 
strains elicit different T-cell responses in human in vitro assays when healthy BCG-vaccinated 339 
individuals are tested (84).  340 
BCG therapy and anti-coagulant drug interactions have also been investigated, but without 341 
conclusive results (87). The possibility of warfarin-associated bladder tumour recurrences following 342 
intravesical BCG has been suggested, although the underlying mechanism is unclear (88). Similarly, 343 
aspirin has been described to decrease recurrences (88, 89). This effect may be explained by local 344 
prevention of tumour cell adhesion and implantation to the urothelium (90, 91). Furthermore, COX-2 345 
inhibiton has been shown to have anti-tumoural effects in canine and mice models of bladder cancer 346 
(92). There has been evidence of COX-2 expression in CIS and invasive urothelial carcinoma, but not 347 
in healthy bladders (92) (the BOXIT trial of celecoxib for reducing recurrence and progression of 348 
NMIBC will report findings in 2014/15). Understanding in this area is limited, and certainly not 349 
enough to justify exposing patients to the risks of stopping warfarin therapy or changing their 350 
regular prescriptions; however, these data may be useful when the mechanism of action of BCG is 351 
better understood.  352 
Germline and/or somatic genetic variation is also likely to play a significant role in an individual’s 353 
response and a tumour's response to BCG. Single nucleotide polymorphisms (SNPs) in IL-10, TGFβ 354 
and IL-4 genes are associated with progression despite BCG therapy (29), whilst other 355 
polymorphisms are associated with lower recurrence rates. Shintani et al. explored the relationship 356 
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between recurrence and urinary cytokines and found that Th1 cytokines are associated with longer 357 
recurrence-free survival, and Th2 cytokines are associated with BCG failure (26, 37). This suggests 358 
that polymorphisms which affect the Th1/Th2 balance have the potential to change the efficacy of 359 
BCG treatment. The genetic variability of cytokine expression is an ongoing area of research, and 360 
although utilising genetic analysis for determining the suitability of patients for BCG therapy is 361 
currently not in clinical use, it may prove beneficial in the future. It is highly feasible, even probable, 362 
that modern genomic and epigenomic analytical platforms will permit the stratification of patients 363 
into those who are likely to respond to BCG, and those who are not, based upon an initial tumour 364 
biopsy. However, until such platforms enter routine clinical practice, the measurement of urinary 365 
cytokines as described above appears to demonstrate the most promise in the short to medium-366 
term, notwithstanding issues of reproducibility and timing of measurement.  367 
 As described above, there is evidence to suggest certain cytokines either reduce or promote the 368 
effects of BCG. For example, identification of the inhibitory actions of IL-10 by Luo et al. suggest that 369 
high levels of IL-10 correlate with lower cytotoxic activity (59), and in more recent studies IL-10 370 
blockade using anti-IL-10 neutralising monoclonal antibody and IL-10 receptor blockade has been 371 
shown to enhance BCG Th1 responses in preclinical models, with better tumour-free survival rates. 372 
These studies also found significantly enhanced levels of Th1 responses, including higher levels of 373 
IFN-γ, with the use of anti-IL-10 receptor 1 monoclonal antibody in mice models (62, 63, 93). 374 
Translating these promising findings from in vivo preclinical models into early-phase clinical trials 375 
should be considered a priority for the field. Mechanisms specific to BCG, such as TRAIL, should also 376 
be considered. Therefore, combining BCG with cytokine-specific blockade or promotion may 377 
increase effectiveness. However, when altering cytokine activity, consideration should also be given 378 
to side effects: increasing efficacy may reduce tolerability, and the two should be considered 379 
together since non-compliance due to side effects would be counter-productive. 380 
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To reduce adverse effects, alternatives to live BCG have been suggested. Whilst utilising live BCG is 381 
standard practice, it produces significant side effects; alternatively, cytokine-only therapy is much 382 
better tolerated, although single cytokine therapy has not proved successful. Having identified 383 
specific cytokines that are involved in the anti-tumour response, it would be useful to test instillation 384 
of a combination of cytokines. It would also be valid to test the differences in efficacy and side 385 
effects of dead versus live BCG, given that dead BCG also induces the necessary inflammatory 386 
cascade, whilst live BCG is responsible for the side effects. If dead BCG produces a less effective 387 
response, it could be feasible to supplement the response with single cytokine therapy or cytokine 388 
promotion; alternatively, it may be valid to assess induction with live BCG and maintenance therapy 389 
with dead BCG (10). 390 
This review has a number of limitations. Firstly, we have used a non-systematic approach to try to 391 
identify the most pertinent studies in the field, but undoubtedly we have not carried out an 392 
exhaustive review of all studies in the field. Our non-systematic approach is also a reflection of the 393 
heterogeneity of source data and publications, with such data acquired from multiple studies 394 
(mostly small in size), each utilising different treatment regimens and procedures for cytokine 395 
evaluation and measurement, making direct comparisons difficult. As discussed above, uniformity in 396 
such methodology could greatly improve research in this area. Meta-analyses of data regarding the 397 
most promising cytokines described above could be appropriate and valuable, but such analyses are 398 
beyond the scope of this review. However, it is our opinion that a strategy of co-ordinated early-399 
phase studies in combination with comprehensive laboratory-based analyses is required to progress 400 
the field and to optimise the management of patients receiving BCG for NMIBC. Unfortunately, 401 
research funding for bladder cancer is poor when compared to other common malignancies (94-96), 402 
and this needs to be urgently addressed before such progress can be made. 403 
404 
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CONCLUSION 405 
The mechanism of action for BCG is complex and variable, and a full understanding remains elusive. 406 
It is likely that many elements of the immune system respond to BCG instillation; however, which of 407 
these are necessary for the clinical efficacy of BCG immunotherapy remains to be answered. 408 
Likewise, which of these are detrimental in terms of side effects is also unknown. Further research 409 
should focus on combinations of BCG and cytokine therapy, as well as indicators of an individual’s 410 
response to treatment, such as predictive cytokines and genetic variants. Although these areas are 411 
unlikely to be fully elucidated or utilised in clinical practice in the immediate future, further research 412 
may shed light on determining how we can distinguish between patients who may benefit from BCG 413 
treatment, how we can optimise BCG responses, and how we can reduce the side effects that limit 414 
the use of BCG for many patients.  415 
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EXECUTIVE SUMMARY 416 
Introduction 417 
• Intravesical instillation of Bacillus Calmette-Guerin (BCG) is an effective therapy for non-muscle-418 
invasive bladder cancer. 419 
• Intravesical BCG therapy is associated with significant side effects. 420 
• The precise mechanism of action of BCG remains elusive. 421 
• Understanding the mechanism of action may permit improved efficacy, improved patient 422 
selection and a reduction in side effects. 423 
The Immune Response 424 
• The two main subsets of T cells are CD4 helper T cells and CD8 cytotoxic T cells, leading to the 425 
concept of Th1 and Th2 subsets. 426 
• Th1 cytokines produce pro-inflammatory responses; Th2 cytokines counteract the inflammatory 427 
response and are also involved in antibody reactions. 428 
Cytokines in BCG 429 
• Following intravesical BCG therapy the cytokine milieu of the bladder and urine is complex and 430 
variable. 431 
• IL-10 and TRAIL may represent therapeutic targets for improving BCG efficacy. 432 
Predictive cytokines 433 
• IL-2, IL-8 and TRAIL show promise as predictive cytokines for BCG therapeutic responses. 434 
Future Perspective 435 
• Further early-phase studies combined with laboratory-based analyses are required to optimise 436 
the management of patients receiving intravesical BCG for NMIBC. 437 
438 
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TABLE & FIGURE LEGENDS 723 
Table 1: Modal week of first appearance of a particular cytokine (from Jackson et al. (25)). Note that 724 
some cytokines (IL-6) are readily detected after the first week, whilst for others (IL-2, IFN-γ) several 725 
rounds of therapy are first required. 726 
 727 
Table 2: Predictive cytokines - Levels of IL-2 and IL-8 and prediction of response to BCG therapy in 728 
various studies. The values used to divide responders and non-responders are shown, with the statistical 729 
significance of these differences. The range or standard deviation (SD) of the cytokines detected in these 730 
groups is also given, where available. 731 
 732 
Supplementary Table 1: Summary of cytokine concentrations following final BCG instillation, expressed 733 
either as a snapshot concentration (e.g. pg/ml) or as a measurement over a specified time period (e.g. 734 
ng/2h where h=hours). 735 
 736 
Figure 1: A pictorial representation of the cellular and cytokine mechanisms associated with therapeutic 737 
response or failure to intravesical BCG immunotherapy for NMIBC.  738 
739 
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Table 1 740 
  Cytokine appearance in weeks following once weekly BCG instillations  
  IL-1 IL-2 IL-4 IL-6 IL-8 IL-10 TNFα IFNγ ICAM1 
Jackson  
et al. 
(25) 1 4 - 1 1 1 2 3 1 
 741 
742 
32 
 
Table 2. 743 
 Non-responder Responder P-value 
Patients 
(Numbers) 
Recurrence 
rate 
Median 
Follow-up 
(Months) 
Reference 
IL-2 
0.18ng/24h 
(±0.43) 
10.6ng/24h 
(±12.9) 
<0.01 20 30% 46.9 
Watanabe 
et al. (72) 
<27  pg/μmol 
creatinine 
>27 pg/μmol 
creatinine 
0.0009 37 59.5% 29 
Saint et al. 
(77) 
<0.34 U/μmol 
creatinine 
>0.34 U/μmol 
creatinine 
0.003 23 
</> 6 
months 
- 
de Reijke  
et al. (78) 
IL-8 
<4000 ng/12h  
(232-8497ng) 
>4000 ng/12h 
(432-8497ng) 
<0.05 28 42.9% 66 
Thalmann 
et al. (66) 
<4000  ng/6h      
(1735.5 
±1596ng) 
>4000 ng/6h    
(6961.4 
±3095ng) 
<0.0002 20 50% 36.5 
Thalmann 
et al. (73) 
<400pg/ml 
@4h  (261.82 
±182.66) 
>400pg/ml 
@4h (1099.33 
±708.51) 
0.001 26 42.3% 24 
Kumar et al. 
(74) 
 744 
745 
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Supplementary Table 1 746 
 
 
 Cytokine level following 6th instillation of BCG from various studies  
0hrs 2hrs 4hrs 6hrs 8hrs 12hrs 24hrs Reference 
IL-1 
20ng/2h 10ng/2h 85ng/2h 30ng/2h 45ng/2h   Bohle & Brandau (36) 
0.03pg/mL 
(±0.07)  
1.72pg/mL  
(±1.55)  
0.52pg/mL 
(±0.62)  
0.06pg/mL 
(±0.09) 
Shintani  et 
al. (26) 
     
29.9 
pg/12h 
(2-118) 
 Jackson et al. (25) 
      23.38ng/24h (±61.64) 
Watanabe et 
al. (72) 
IL-2 
0ng/2h 
 
10ng/2h 
 
300ng/2h 
 
100 
ng/2h 
20ng/2h 
   
Bohle & 
Brandau (36) 
     
74.4 
pg/12h 
(0-666) 
 Jackson et al. (25) 
      7.52ng/24h (±11.75) 
Watanabe et 
al. (72) 
IL-6 
     
245 
pg/12h 
(17-747) 
 Jackson et al. (25) 
      
100.04ng 
/24h 
(±107.31) 
Watanabe et 
al. (72) 
IL-8 
0.42pg/mL 
(±1.34)  
7.75pg/mL 
(±13.56)  
6.23pg/mL 
(±10.33)  
1.44pg/mL 
(±2.58) 
Shintani  et 
al. (26) 
     
4.8 
mg/12h 
(0.1-29) 
 Jackson et al. (25) 
      
222.27 
ng/24h 
(±144.64) 
Watanabe et 
al. (72) 
IL-10 
     
51.3 
pg/12h 
(0-400) 
 Jackson et al. (25) 
      
115.77ng/24
h 
(±191.46) 
Watanabe et 
al. (72) 
TNFα 
1 ng/2h 
 
8ng/2h 
 
7ng/2h 
 
2ng/2h 
 
3ng/2h 
   
Bohle & 
Brandau (36) 
0.01pg/mL 
(±0.02)  
5.08pg/mL 
(±7.89)  
0.03pg/mL 
(±0.05)  
0.01pg/mL 
(±0.02) 
Shintani  et 
al. (26) 
     
80.4 
pg/12h 
(0-363) 
 Jackson et al. (25) 
      
488.27 
ng/24h 
(±774.17) 
Watanabe et 
al. (72) 
IFNγ 
0.01pg/mL 
(±0.06)  
1.47pg/mL 
(±5.47)  
0.35pg/mL 
(±1.34)  
0.02pg/mL 
(±0.05) 
Shintani  et 
al. (26) 
     
5900 
U/12h 
(0-23000) 
 Jackson et al. (25) 
      
134.11 
ng/24h 
(±179.10) 
Watanabe et 
al. (72) 
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Figure 1 747 
 748 
